Want to see FATE full AI Analyst Report?
FATE Stock Chart & Stats
$1.39
-$0.10(-5.71%)
At close: 4:00 PM EST
$1.39
-$0.10(-5.71%)
Day’s Range― - ―
52-Week Range$0.91 - $3.23
Previous CloseN/A
Volume630.90K
Average Volume (3M)4.13M
Market Cap
$324.03M
Enterprise Value$46.00
Total Cash (Recent Filing)$174.82M
Total Debt (Recent Filing)$76.78M
Price to Earnings (P/E)―
Beta2.54
Next Earnings
Aug 05, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding116,559,190
10 Day Avg. Volume3,404,042
30 Day Avg. Volume4,125,941
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)17.56
P/FCF Ratio-1.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.98Price Target Upside258.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.08
Revenue Forecast (FY)$5.25M
Bulls Say, Bears Say
Bulls Say
Scalable IPSC Off-the-shelf PlatformFate’s iPSC-based, off-the-shelf CAR-T/NK platform targets scalable, multi-patient manufacturing and outpatient-enabled therapies. The planned Phase 2 registrational RECLAIM-LN trial and next-gen candidates create a durable path toward regulatory validation and eventual commercial scale if clinical results confirm efficacy.
Manageable Leverage And Positive EquityReported debt-to-equity around 0.43 and positive equity provide relative balance-sheet room compared with high-debt peers. This standing supports continuing R&D and partnering discussions without immediate solvency pressure, preserving strategic optionality while clinical programs advance.
Shareholder And Governance SupportInvestor approval of directors, auditor ratification, and authorization of additional incentive shares signal governance stability and shareholder alignment. That facilitates retention, board continuity and the use of equity incentives to attract talent and partners critical for long-term clinical and commercial execution.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow north of $100M annually means the company cannot self-fund development and will likely need external capital or partnerships. Recurring cash burn constrains runway, increases dilution risk, and forces trade-offs in program prioritization over the medium term.
Minimal And Declining RevenueWith only ~$6.3M TTM revenue and declining top-line, Fate has no meaningful commercial cash inflow to offset R&D spend. Negative gross profit and heavily negative margins indicate operations remain pre-commercial, increasing dependence on financing and making business sustainability contingent on clinical success.
Eroding Equity From Cumulative LossesA dramatic decline in reported equity over several years reflects accumulated losses that weaken the balance sheet. This erosion reduces borrowing and strategic flexibility, raises the likelihood of dilutive financings, and heightens long-term solvency risk if clinical readouts or partnerships do not materialize.
Fate Therapeutics News
FATE FAQ
What was Fate Therapeutics Inc’s price range in the past 12 months?
Fate Therapeutics Inc lowest stock price was $0.91 and its highest was $3.23 in the past 12 months.
What is Fate Therapeutics Inc’s market cap?
Fate Therapeutics Inc’s market cap is $324.03M.
When is Fate Therapeutics Inc’s upcoming earnings report date?
Fate Therapeutics Inc’s upcoming earnings report date is Aug 05, 2026 which is in 15 days.
How were Fate Therapeutics Inc’s earnings last quarter?
Fate Therapeutics Inc released its earnings results on May 13, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.02.
Is Fate Therapeutics Inc overvalued?
According to Wall Street analysts Fate Therapeutics Inc’s price is currently Undervalued.
Does Fate Therapeutics Inc pay dividends?
Fate Therapeutics Inc does not currently pay dividends.
What is Fate Therapeutics Inc’s EPS estimate?
Fate Therapeutics Inc’s EPS estimate is -0.27.
How many shares outstanding does Fate Therapeutics Inc have?
Fate Therapeutics Inc has 116,559,190 shares outstanding.
What happened to Fate Therapeutics Inc’s price movement after its last earnings report?
Fate Therapeutics Inc reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went down -5.111%.
Which hedge fund is a major shareholder of Fate Therapeutics Inc?
Currently, no hedge funds are holding shares in FATE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.98 (258.00% Upside)
$4.98 (258.00% Upside)
Blogger Sentiment
Neutral
FATE Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 188.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $102.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.53%
Trailing 12-Months
Company Description
Fate Therapeutics Inc
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
FATE Stock 12 Month Forecast
Average Price Target
$4.98
▲(258.00% Upside)
Technical Analysis
Ownership Overview
12.84% Insiders
12.63% Mutual Funds
0.14% Other Institutional Investors
68.96% Public Companies and
Individual Investors